Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 5/20 | 0.70 |
| ▸ | MLNR | O43193 | 2/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.54 |
| ▸ | UBE2M | P61081 | 2/20 | 0.54 |
| ▸ | DCUN1D1 | Q96GG9 | 2/20 | 0.54 |
| ▸ | MEN1 | O00255 | 1/20 | 0.54 |
| ▸ | TEAD1 | P28347 | 2/20 | 0.53 |
| ▸ | BTK | Q06187 | 1/20 | 0.51 |
| ▸ | PHGDH | O43175 | 4/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25785164 | 0.93 | EPHX2 (0.61) | EPHX2MLNRKMT2AUBE2MDCUN1D1 | |
| SCHEMBL25785151 | 0.93 | EPHX2 (0.61) | EPHX2MLNRKMT2AUBE2MDCUN1D1 | |
| SCHEMBL25785146 | 0.91 | EPHX2 (0.59) | EPHX2MLNRKMT2AUBE2MDCUN1D1 | |
| SCHEMBL21958169 | 0.89 | MLNR (0.56) | EPHX2MLNRKMT2AUBE2MDCUN1D1 | |
| SCHEMBL9310541 | 0.87 | LMNA (0.59) | EPHX2MLNRKMT2AUBE2MDCUN1D1 | |
| SCHEMBL21856356 | 0.86 | EPHX2 (0.57) | EPHX2MLNRKMT2AUBE2MDCUN1D1 | |
| SCHEMBL21856361 | 0.86 | EPHX2 (0.57) | EPHX2MLNRKMT2AUBE2MDCUN1D1 | |
| SCHEMBL24780719 | 0.83 | TEAD1 (0.71) | EPHX2MLNRKMT2ADCUN1D1TEAD1 | |
| SCHEMBL21957254 | 0.83 | TEAD1 (0.71) | EPHX2MLNRKMT2ADCUN1D1TEAD1 | |
| SCHEMBL21958163 | 0.83 | TEAD1 (0.71) | EPHX2MLNRKMT2ADCUN1D1TEAD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220402869-A1 | TRANSCRIPTIONAL ENHANCED ASSOCIATE DOMAIN (TEAD) TRANSCRIPTION FACTOR INHIBITORS AND USES THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2022-12-22 | — | — | US | disclosed |
| WO-2020081572-A1 | TRANSCRIPTIONAL ENHANCED ASSOCIATE DOMAIN (TEAD) TRANSCRIPTION FACTOR INHIBITORS AND USES THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2020-04-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220402869-A1 | TRANSCRIPTIONAL ENHANCED ASSOCIATE DOMAIN (TEAD) TRANSCRIPTION FACTOR INHIBITORS AND USES THEREOF | TEAD1, TEAD4, TEAD2 | EPHX2 2437/4885MLNR 3760/4885KMT2A 2881/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.